TLP has been specifically created to serve mid-sized and emerging bio-pharma companies. SME’s may not need the full panoply of commercial and access services provided by the big agencies. However, there are synergies and advantages in working with a single external partner. We have the capabilities and experience to provide all pivotal, pre-launch services and advice in a flexible and cost-effective package. Our range of support – including market access, medical affairs and commercial strategy – can be deployed and varied to exactly match client needs at different stages of the value chain and business maturity. With TLP you can have the best of both worlds in an affordable, agile and effective one-stop-shop.
Market Access Specialist
Pete has over 20 years’ experience as a Health Economist and Market Access Lead in the Pharmaceutical Industry. He trained as a Hospital Pharmacist in London and was a clinical pharmacist in the UK NHS for 3 years. After a role as Payer Pharmacist in Oxford in charge of formulary at a tertiary care hospital he joined the pharma industry where he trained and qualified as a Health Economist at GSK. Pete undertook his first NICE submission in 1998.
More recently he held posts as Head of EU Market Access for Wyeth and Executive Director, Head of UK Market Access for Grunenthal Ltd. In these positions Pete gained extensive experience writing technology appraisals and leading NICE submissions. He was also in charge of health outcomes, market access marketing, government affairs and field-based payer interface as well as value dossier development and HOL support. He is an expert in EU Pricing & Reimbursement and has worked in oncology, rheumatology, dermatology, pain management, gastroenterology and hepatology.
Dr Rob Barden MB, DRCOG
Independent Pharmaceutical Physician
A qualified Doctor, Rob has spent most of his professional career as a Pharmaceutical Physician, mainly in Medical Affairs, but also in Product Development. Having initially been a GP in the RAF and later in Australia, he spent his initial years in pharma as a Medical Advisor with Abbott Labs, before taking on similar roles with Ashbourne Pharmaceuticals and Wyeth. For the past 14 years he has been working as an independent Pharmaceutical Physician, undertaking assignments with a variety of companies including AstraZeneca, Wyeth, BMS, GSK, Roche, Vertex and J&J (amongst others).
Rob has worked across a wide range of therapeutic areas including immunology, oncology & supportive care, dermatology, gastroenterology, anti-infectives, diabetes, haematology and neuropsychiatry. He is an ABPI and MHRA approved promotional copy approval Signatory. His other main areas of experience and interest include Health Economics (Clinical input into multiple NICE & SMC submissions & Stakeholder management), Market Access, Clinical Overviews, Advisory Boards participation (Clinical, Payer, Specialist nurses), Clinical trials management, MSL training and Drug safety.
Tim is a highly creative and strategic thinker with a wealth of experience in the healthcare sector plus a track record of success in commercial business support and consulting. A grounding in clinical research and sales and marketing within the pharmaceutical industry proved to be the perfect launch pad for a role in strategic consulting and healthcare communications. He has worked at Abbott, J&J and Searle. He is also an Angel Investor, non-Executive Director and associate consultant for a fledging Investment Fund.
A skilled meeting facilitator, trainer and expert in pre-launch commercial strategy, he has developed and run many workshops in both formal and informal settings for internal and external audiences. Furthermore he is an accomplished presenter equally comfortable and effective on a podium at a large meeting, chairing an ad board or in an interactive workshop setting.
A graduate in Zoology, Tim also has a Masters degree in Neurological Science. Within the pharm industry and agencies he has been involved in the launch of >20 products. Tim has in-depth knowledge and experience in most major therapeutic areas but has particular expertise in oncology, cardiovascular, CNS, and anti-infectives.